Pune, June, 2020: Amid the novel coronavirus outbreak with more than 1 lac active cases and the demise of 12 thousand people, a positive ray of light has been brought by Glenmark Pharmaceuticals. They came up with a drug called FabiFlu to treat mild to moderate cases of COVID-19. It is the first food-based oral medication approved for the treatment of this deadly virus. The dosage of this medicine is 1800 mg twice daily on day one followed by 800mg twice daily up to day 14 on providing a prescription.
The Drug Controller General of India (DCGI) has approved to market and manufacture this medicine on Friday. This information was given by Glenmark Pharmaceuticals on Saturday, 20th June in Mumbai to the media.
This antiviral drug Fabipiravir has been launched under the brand name FabiFlu for the treatment of coronavirus patients with Rs. 103/- per tablet. According to the company, this drug will be able to treat more than 80 thousand patients in the first month considering two strips per patient. They will keep an eye on the recovery rate and post that they will work to meet the healthcare needs of the nation.
Glenn Saldanha, Chairman and MD of Glenmark Pharmaceuticals said, “With more cases of coronavirus rising in the Indian subcontinent, the approval of this drug was a need of the hour. Our healthcare system is under great pressure now. We hope to reduce this pressure with the availability of this treatment.”
The drug would be available in both hospitals and retail channels. The Mumbai based company will make the drug available for both private and public healthcare centres as and when required across the nation. The clinical trial of FabiFlu showed positive results on patients with mild infection. The drug can also be used to treat patients with minor infection having diabetes and heart disease.
After this initiative, many other pharmaceutical companies from Delhi, Bangalore, Hyderabad have submitted their manufactured drugs for approval to be launched in India.